Blockade of Interleukin 6 Signaling Induces Marked Neutropenia in Patients with Rheumatoid Arthritis: Figure 1.
Authors:
- Ichiro NakamuraINIchiro Nakamura
- Yasunori OmataYOYasunori Omata
- Masashi NaitoMNMasashi Naito
- Katsumi ItoKIKatsumi Ito
Open Access
- 9 February 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (2) , 459
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals of the Rheumatic Diseases, 2007
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- Roles of Interleukin‐6 in Activation of STAT Proteins and Recruitment of Neutrophils duringEscherichia coliPneumoniaThe Journal of Infectious Diseases, 2006
- IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute InflammationImmunity, 2001
- Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependentJournal of Leukocyte Biology, 1995